WO2007024993A3 - Fused aminopiperidines as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes - Google Patents

Fused aminopiperidines as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes Download PDF

Info

Publication number
WO2007024993A3
WO2007024993A3 PCT/US2006/032989 US2006032989W WO2007024993A3 WO 2007024993 A3 WO2007024993 A3 WO 2007024993A3 US 2006032989 W US2006032989 W US 2006032989W WO 2007024993 A3 WO2007024993 A3 WO 2007024993A3
Authority
WO
WIPO (PCT)
Prior art keywords
dipeptidyl peptidase
diabetes
inhibitors
prevention
treatment
Prior art date
Application number
PCT/US2006/032989
Other languages
French (fr)
Other versions
WO2007024993A2 (en
Inventor
Jason M Cox
Scott D Edmondson
Anthony Mastracchio
Original Assignee
Merck & Co Inc
Jason M Cox
Scott D Edmondson
Anthony Mastracchio
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck & Co Inc, Jason M Cox, Scott D Edmondson, Anthony Mastracchio filed Critical Merck & Co Inc
Priority to US11/990,037 priority Critical patent/US8017624B2/en
Priority to EP06813692A priority patent/EP1921917B1/en
Priority to JP2008528132A priority patent/JP5075125B2/en
Priority to AU2006283062A priority patent/AU2006283062B2/en
Priority to AT06813692T priority patent/ATE549926T1/en
Priority to CA2619111A priority patent/CA2619111C/en
Publication of WO2007024993A2 publication Critical patent/WO2007024993A2/en
Publication of WO2007024993A3 publication Critical patent/WO2007024993A3/en
Priority to AU2011201488A priority patent/AU2011201488B2/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/26—Androgens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Abstract

The present invention is directed to novel substituted fused aminopiperidines which are inhibitors of the dipeptidyl peptidase-IV enzyme ('DPP-IV inhibitors') and which are useful in the treatment or prevention of diseases in which the dipeptidyl peptidase-IV enzyme is involved, such as diabetes and particularly Type 2 diabetes. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which the dipeptidyl peptidase-IV enzyme is involved.
PCT/US2006/032989 2004-11-29 2006-08-22 Fused aminopiperidines as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes WO2007024993A2 (en)

Priority Applications (7)

Application Number Priority Date Filing Date Title
US11/990,037 US8017624B2 (en) 2005-08-26 2006-08-22 Fused aminopiperidines as dipeptidyi peptidase-IV inhibitors for the treatment or prevention of diabetes
EP06813692A EP1921917B1 (en) 2005-08-26 2006-08-22 Fused aminopiperidines as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes
JP2008528132A JP5075125B2 (en) 2005-08-26 2006-08-22 Condensed aminopiperidines as dipeptidyl peptidase IV inhibitors for the treatment or prevention of diabetes
AU2006283062A AU2006283062B2 (en) 2005-08-26 2006-08-22 Fused aminopiperidines as dipeptidyl peptidase-IV inhibitors for the treatment or prevention of diabetes
AT06813692T ATE549926T1 (en) 2005-08-26 2006-08-22 CONDENSED AMINOPIPERIDINES AS DIPEPTIDYLPEPTIDASE IV INHIBITORS FOR THE TREATMENT OR PREVENTION OF DIABETES
CA2619111A CA2619111C (en) 2005-08-26 2006-08-22 Fused aminopiperidines as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes
AU2011201488A AU2011201488B2 (en) 2004-11-29 2011-04-01 Fused aminopiperidines as dipeptidyl peptidase-IV inhibitors for the treatment or prevention of diabetes

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US71175605P 2005-08-26 2005-08-26
US60/711,756 2005-08-26

Publications (2)

Publication Number Publication Date
WO2007024993A2 WO2007024993A2 (en) 2007-03-01
WO2007024993A3 true WO2007024993A3 (en) 2007-10-11

Family

ID=37772353

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2006/032989 WO2007024993A2 (en) 2004-11-29 2006-08-22 Fused aminopiperidines as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes

Country Status (7)

Country Link
US (1) US8017624B2 (en)
EP (1) EP1921917B1 (en)
JP (1) JP5075125B2 (en)
AT (1) ATE549926T1 (en)
AU (1) AU2006283062B2 (en)
CA (1) CA2619111C (en)
WO (1) WO2007024993A2 (en)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7718667B2 (en) 2004-09-28 2010-05-18 Merck Sharp & Dohme Corp. Fused aminopiperidines as dipeptidyl peptidase-IV inhibitors for the treatment or prevention of diabetes
JP4999698B2 (en) * 2004-11-29 2012-08-15 メルク・シャープ・エンド・ドーム・コーポレイション Fused aminopiperidines as dipeptidyl peptidase-IV inhibitors for the treatment or prevention of diabetes
JP5069678B2 (en) 2005-05-25 2012-11-07 メルク・シャープ・エンド・ドーム・コーポレイション Aminocyclohexane as a dipeptidyl peptidase IV inhibitor for the treatment or prevention of diabetes
AU2006326564B2 (en) 2005-12-14 2011-06-23 Merck Sharp & Dohme Corp. Fused aminopiperidines as dipeptidyl peptidase-4 inhibitors for the treatment or prevention of diabetes
CA2636757A1 (en) 2006-01-25 2007-08-02 Tesfaye Biftu Aminocyclohexanes as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes
JP5161795B2 (en) 2006-02-15 2013-03-13 メルク・シャープ・エンド・ドーム・コーポレイション Aminotetrahydropyran as a dipeptidyl peptidase IV inhibitor for the treatment or prevention of diabetes
TW200806669A (en) 2006-03-28 2008-02-01 Merck & Co Inc Aminotetrahydropyrans as dipeptidyl peptidase-IV inhibitors for the treatment or prevention of diabetes
US7812027B2 (en) 2006-05-16 2010-10-12 Merck Sharp & Dohme Corp. Substitued [1,2,4]triazolo[1,5-a]pyrazines as dipeptidyl peptidase-IV inhibitors for the treatment or prevention of diabetes
WO2007148185A2 (en) 2006-06-21 2007-12-27 Pfizer Products Inc. Substituted 3 -amino- pyrrolidino-4 -lactams as dpp inhibitors
RU2009108280A (en) 2006-08-08 2010-09-20 Санофи-Авентис (Fr) Arylamino-arylalkyl-substituted imidazolidine-2,4-dione, methods for their preparation containing these compounds and their use
EP2025674A1 (en) 2007-08-15 2009-02-18 sanofi-aventis Substituted tetra hydro naphthalines, method for their manufacture and their use as drugs
AR072707A1 (en) 2008-07-09 2010-09-15 Sanofi Aventis HETEROCICLIC COMPOUNDS, PROCESSES FOR THEIR PREPARATION, DRUGS THAT UNDERSTAND THESE COMPOUNDS AND THE USE OF THEM
JO2870B1 (en) 2008-11-13 2015-03-15 ميرك شارب اند دوهم كورب Aminotetrahydropyrans as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes
WO2010068601A1 (en) 2008-12-08 2010-06-17 Sanofi-Aventis A crystalline heteroaromatic fluoroglycoside hydrate, processes for making, methods of use and pharmaceutical compositions thereof
US8785608B2 (en) 2009-08-26 2014-07-22 Sanofi Crystalline heteroaromatic fluoroglycoside hydrates, pharmaceuticals comprising these compounds and their use
CA2771352A1 (en) 2009-09-02 2011-03-10 Merck Sharp & Dohme Corp. Aminotetrahydropyrans as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes
US8716482B2 (en) 2009-09-25 2014-05-06 Merck Sharp & Dohme Corp. Substituted aminopiperidines as dipeptidyl peptidase-IV inhibitors for the treatment of diabetes
WO2011103256A1 (en) 2010-02-22 2011-08-25 Merck Sharp & Dohme Corp. Substituted aminotetrahydrothiopyrans and derivatives thereof as dipeptidyl peptidase-iv inhibitors for the treatment of diabetes
WO2011107494A1 (en) 2010-03-03 2011-09-09 Sanofi Novel aromatic glycoside derivatives, medicaments containing said compounds, and the use thereof
WO2011146358A1 (en) 2010-05-21 2011-11-24 Merck Sharp & Dohme Corp. Substituted seven-membered heterocyclic compounds as dipeptidyl peptidase-iv inhibitors for the treatment of diabetes
EP2582709B1 (en) 2010-06-18 2018-01-24 Sanofi Azolopyridin-3-one derivatives as inhibitors of lipases and phospholipases
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
EP2648517B1 (en) 2010-12-06 2015-08-05 Merck Sharp & Dohme Corp. Tricyclic heterocycles useful as dipeptidyl peptidase-iv inhibitors
EP2683705B1 (en) 2011-03-08 2015-04-22 Sanofi Di- and tri-substituted oxathiazine derivates, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
US8901114B2 (en) 2011-03-08 2014-12-02 Sanofi Oxathiazine derivatives substituted with carbocycles or heterocycles, method for producing same, drugs containing said compounds, and use thereof
WO2012120055A1 (en) 2011-03-08 2012-09-13 Sanofi Di- and tri-substituted oxathiazine derivates, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
EP2683700B1 (en) 2011-03-08 2015-02-18 Sanofi Tetra-substituted oxathiazine derivatives, method for their preparation, their usage as medicament and medicament containing same and its use
US8828995B2 (en) 2011-03-08 2014-09-09 Sanofi Branched oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
CA2838748A1 (en) 2011-06-29 2013-01-03 Merck Sharp & Dohme Corp. Process for preparing chiral dipeptidyl peptidase-iv inhibitors
WO2013006526A2 (en) 2011-07-05 2013-01-10 Merck Sharp & Dohme Corp. Tricyclic heterocycles useful as dipeptidyl peptidase-iv inhibitors
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
EP2760862B1 (en) 2011-09-27 2015-10-21 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2013122920A1 (en) 2012-02-17 2013-08-22 Merck Sharp & Dohme Corp. Dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes
US9315508B2 (en) 2012-07-23 2016-04-19 Merck Sharp & Dohme Corp. Treating diabetes with dipeptidyl peptidase-IV inhibitors
EP2874626A4 (en) 2012-07-23 2016-03-23 Merck Sharp & Dohme Treating diabetes with dipeptidyl peptidase-iv inhibitors
TWI500613B (en) 2012-10-17 2015-09-21 Cadila Healthcare Ltd Novel heterocyclic compounds
WO2014064215A1 (en) 2012-10-24 2014-05-01 INSERM (Institut National de la Santé et de la Recherche Médicale) TPL2 KINASE INHIBITORS FOR PREVENTING OR TREATING DIABETES AND FOR PROMOTING β-CELL SURVIVAL
JP6574474B2 (en) 2014-07-21 2019-09-11 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． Process for producing chiral dipeptidyl peptidase-IV inhibitor
WO2016151018A1 (en) 2015-03-24 2016-09-29 INSERM (Institut National de la Santé et de la Recherche Médicale) Method and pharmaceutical composition for use in the treatment of diabetes

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040242568A1 (en) * 2003-03-25 2004-12-02 Syrrx, Inc. Dipeptidyl peptidase inhibitors
US20050070535A1 (en) * 2003-08-13 2005-03-31 Syrrx, Inc. Dipeptidyl peptidase inhibitors
US20050131019A1 (en) * 2003-09-04 2005-06-16 Zhonghua Pei Pharmaceutical compositions as inhibitors of dipeptidyl peptidase-IV (DPP-IV)

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60316416T2 (en) * 2002-03-25 2008-06-26 Merck & Co., Inc. HETEROCYCLIC BETA-AMINO COMPOUNDS AS INHIBITORS OF DIPEPTIDYLPEPTIDASE FOR TREATMENT OR PREVENTION OF DIABETES
JP2003300977A (en) * 2002-04-10 2003-10-21 Sumitomo Pharmaceut Co Ltd Xanthine derivative
DE10238477A1 (en) * 2002-08-22 2004-03-04 Boehringer Ingelheim Pharma Gmbh & Co. Kg New purine derivatives, their production and their use as medicines
AU2005265148B2 (en) 2004-06-21 2011-01-20 Merck Sharp & Dohme Corp. Aminocyclohexanes as dipeptidyl peptidase-IV inhibitors for the treatment or prevention of diabetes
CN101005877A (en) 2004-08-23 2007-07-25 默克公司 Fused triazole derivatives as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes
US7718667B2 (en) 2004-09-28 2010-05-18 Merck Sharp & Dohme Corp. Fused aminopiperidines as dipeptidyl peptidase-IV inhibitors for the treatment or prevention of diabetes
EP1796669B1 (en) 2004-10-01 2010-09-22 Merck Sharp & Dohme Corp. Aminopiperidines as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes
JP4999698B2 (en) * 2004-11-29 2012-08-15 メルク・シャープ・エンド・ドーム・コーポレイション Fused aminopiperidines as dipeptidyl peptidase-IV inhibitors for the treatment or prevention of diabetes
JP5069678B2 (en) 2005-05-25 2012-11-07 メルク・シャープ・エンド・ドーム・コーポレイション Aminocyclohexane as a dipeptidyl peptidase IV inhibitor for the treatment or prevention of diabetes
AU2006326564B2 (en) 2005-12-14 2011-06-23 Merck Sharp & Dohme Corp. Fused aminopiperidines as dipeptidyl peptidase-4 inhibitors for the treatment or prevention of diabetes
CA2636757A1 (en) 2006-01-25 2007-08-02 Tesfaye Biftu Aminocyclohexanes as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040242568A1 (en) * 2003-03-25 2004-12-02 Syrrx, Inc. Dipeptidyl peptidase inhibitors
US20050070535A1 (en) * 2003-08-13 2005-03-31 Syrrx, Inc. Dipeptidyl peptidase inhibitors
US20050131019A1 (en) * 2003-09-04 2005-06-16 Zhonghua Pei Pharmaceutical compositions as inhibitors of dipeptidyl peptidase-IV (DPP-IV)

Also Published As

Publication number Publication date
US20090258894A1 (en) 2009-10-15
CA2619111C (en) 2013-04-09
EP1921917B1 (en) 2012-03-21
US8017624B2 (en) 2011-09-13
JP5075125B2 (en) 2012-11-14
ATE549926T1 (en) 2012-04-15
JP2009506058A (en) 2009-02-12
CA2619111A1 (en) 2007-03-01
WO2007024993A2 (en) 2007-03-01
EP1921917A2 (en) 2008-05-21
AU2006283062B2 (en) 2011-04-14
EP1921917A4 (en) 2010-08-04
AU2006283062A1 (en) 2007-03-01

Similar Documents

Publication Publication Date Title
WO2007024993A3 (en) Fused aminopiperidines as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes
WO2006127530A3 (en) Aminocyclohexanes as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes
WO2006039325A3 (en) Aminopiperidines as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes
WO2006023750A3 (en) Fused triazole derivatives as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes
WO2006078676A3 (en) Bicyclic pyrimidines as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes
WO2006058064A3 (en) Fused aminopiperidines as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes
WO2005011581A3 (en) Hexahydrodiazepinones as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes
WO2007070434A3 (en) Fused aminopiperidines as dipeptidyl peptidase-4 inhibitors for the treatment or prevention of diabetes
WO2005044195A3 (en) Fused phenylalanine derivatives as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes
WO2007087231A3 (en) Aminocyclohexanes as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes
WO2007126745A3 (en) Aminotetrahydropyrans as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes
WO2004069162A3 (en) 3-amino-4-phenylbutanoic acid derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
WO2004064778A3 (en) 3-amino-4-phenylbutanoic acid derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
WO2004103276A3 (en) 3-amino-4-phenylbutanoic acid derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
WO2007097931A3 (en) Aminotetrahydropyrans as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes
WO2007136603A3 (en) Aminotetrahydropyrans as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes
WO2004112701A3 (en) Cyclohexylglycine derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
WO2004037169A3 (en) Beta-amino heterocyclic dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
WO2003082817A3 (en) Beta-amino heterocyclic dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
WO2004050022A8 (en) Phenylalanine derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
CA2504735A1 (en) Phenylalanine derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
WO2004032836A3 (en) Antidiabetic beta-amino heterocylcic dipeptidyl peptidase inhibitors
EP1385508A4 (en) Dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
MY150787A (en) Aminotetrahydropyrans as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of prevention of diabetes
TW200500338A (en) Phenylalanine derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 11990037

Country of ref document: US

ENP Entry into the national phase

Ref document number: 2619111

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2006283062

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2006813692

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2008528132

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2006283062

Country of ref document: AU

Date of ref document: 20060822

Kind code of ref document: A